DMPI Insider Trading Activity and SEC Form 4 Filings
DMPI insider trading summary
No open-market insider purchases or sales of DelMar Pharmaceuticals, Inc. (DMPI) have been reported on SEC Form 4 in the past 12 months.
Latest DMPI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 13, 2019 | John K Bell | Director | Buy | $24K (35,000 @ $0.68) |
| Nov 16, 2017 | John K Bell | Director | Buy | $15K (18,129 @ $0.81) |
| Nov 15, 2017 | John K Bell | Director | Buy | $2K (1,871 @ $0.81) |
| Nov 14, 2017 | Saiid Zarrabian | Interim CEO | Buy | $5K (5,900 @ $0.84) |
| Nov 14, 2017 | Saiid Zarrabian | Interim CEO | Buy | $45K (55,000 @ $0.82) |
| Oct 6, 2017 | Jeffrey Bacha | CEO | Buy | $2K (2,450 @ $0.88) |
| Oct 6, 2017 | Jeffrey Bacha | CEO | Buy | $7K (7,550 @ $0.87) |
| Oct 5, 2017 | Scott Praill | Chief Financial Officer | Buy | $15K (17,500 @ $0.85) |
| Jun 26, 2017 | Jeffrey Bacha | CEO | Buy | $24K (6,700 @ $3.60) |
| Jun 26, 2017 | Scott Praill | Chief Financial Officer | Buy | $15K (4,167 @ $3.60) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.